In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.Morris
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.
Morris Plains, NJ-based Immunomedics plans to use the proceeds of the stock sale to redeem remaining shares of its outstanding preferred stock. In November, the company made an agreement with HFTP Investment to buy 445 of HFTPs preferred shares in the company. The holder of the firms remaining 150 preferred shares, which Immunomedics declined to name, has also agreed to sell those shares to the firm.
The Nonexistence of Perfect Balance in Radiology
September 16th 2024In the elusive pursuit of reconciling case volume and having an appropriate number of radiologists, the proverbial windsurfer may fare better than stand-up paddleboarders and daredevil surfers at navigating the waves of the profession.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.